Clinical trials: Philadelphia Chromosome Negative ALL
Acute Lymphoblastic Leukemia, Adult
Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia
This is a prospective, open-label, non-randomized cohort study evaluating the efficacy and safety of a pediatric-inspired chemotherapy regimen (IH-2014 based) combined with venetoclax and immunotherapy in adult patients with…
- Trial name
- NCT07495631
- Testing
- VDCLP+V, 2VIP, Consolidation Therapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia
Pegasys in Patients With Chronic Myeloid Leukemia (CML)
The goal of this clinical research study is to learn if adding pegylated interferon-alfa 2a (Pegasys) to the TKI that you are already receiving can help to control CML.
- Trial name
- NCT01392170
- Testing
- PEG-IFNá-2a
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Caries
Effect of CPP-ACP With/Without Fl on White Spot Lesion,Salivary pH and fl Release in High Caries Risk Patients
Effect of CPP-ACP pastes with/without Fluoride on White spot lesion progression, salivary pH and fluoride release in high caries risk Patients, over 3 month period using VistaCam, Digital pH meter and Selective ion electrode.
- Trial name
- NCT03656432
- Testing
- CPP-ACP paste
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Cairo University
Primary Hyperoxaluria
Primary Hyperoxaluria Mutation Genotyping/Phenotyping
Specific mutations relating to hyperoxaluria will be determined via DNA analysis by the Mayo RKSC research staff.
- Trial name
- NCT02340689
- Testing
- Genetic Analysis
- Where
- United States
- Volunteers
- 1,235 people
- Sponsor
- Mayo Clinic
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
This phase II trial studies the side effects and best dose of ruxolitinib phosphate and how well it works compared to dasatinib when given with chemotherapy in treating patients with Philadelphia chromosome-like acute…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Ph-Like Acute Lymphoblastic Leukemia
- Trial name
- NCT02420717
- Testing
- Cyclophosphamide, Cytarabine, Dasatinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphocytic, Acute, Adult
Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study
This is a prospective, multicenter, observational study aimed at exploring the efficacy and safety of reduced-dose chemotherapy followed by frontline therapy with blinatumomab in patients aged 15-65 with newly diagnosed…
- Trial name
- NCT06649422
- Testing
- Blinatumomab
- Volunteers
- 36 people
- Sponsor
- Shandong University
Gastro Esophageal Reflux
Esophageal pH-MII Duration: 12 or 24 Hours?
To check whether the first 12 hours of MII-pH recording are sufficient to diagnose gastroesophageal reflux disease (GERD) among newborns/infants, with a diagnostic accuracy similar to 24 hours of recording as currently advised.
- Trial name
- NCT05760274
- Testing
- multichannel intraluminal impedance and pH monitoring (MII/pH)
- Where
- Italy
- Volunteers
- 127 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Premature Birth
Nasogastric/Orogastric Tube Placement Confirmation in Neonates Utilizing Self-contained pH Device, a Feasibility Study
This study is looking at using a self-contained pH device that will assist in confirming placement of a nasogastric or orogastric tube placed in the stomach of hospitalized infants.
- Trial name
- NCT06274944
- Testing
- nasogastric tube placement pH confirmation device
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Minnesota
Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Ph^1^, Absent
Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia
The cure rate for childhood acute lymphoblastic leukemia (ALL) has increased significantly in recent decades and expected cure rates now exceed 85%.
- Conditions
- Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Ph^1^, Absent, B-cell Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT01990807
- Testing
- Idarubicin(IDA)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese Academy of Medical Sciences
Tooth Decay, Intellectual Disability
Probiotics in Special Needs Patients at High Risk for Tooth Decay: a Randomized Controlled Trial.
The goal of this randomized clinical trial is to test the effect orally administration of Probiotics based on Lactobacillus rhamnosus LR04 and Lactobacillus plantarum LP14 as adjuvant in caries prevention in subjects who can not…
- Conditions
- Tooth Decay, Intellectual Disability, Caries,Dental
- Trial name
- NCT06063239
- Testing
- Test Group, Positive Control, Negative Control
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- G. d'Annunzio University
Pulmonary Hypertension
Insights Into Pediatric Pulmonary Hypertension: A Real-World Registry of Epidemiology and Outcomes
Pediatric pulmonary hypertension (PH) shares similarities with PH in adulthood, but specific differences still require unique approaches.
- Trial name
- INSPIRE-PPH (NCT07495774)
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Guangdong Provincial People's Hospital
Neonatal Acidemia and Hypoxia
Hypoxia Profiles Identified in Term Newborns With Cord pH <7.00
Severe neonatal acidosis is an identified risk factor for neonatal encephalopathies and severe neurological sequelae such as cerebral palsy.
- Trial name
- RCFHypA (NCT07333599)
- Where
- France
- Volunteers
- 400 people
- Sponsor
- University Hospital, Strasbourg, France
Preoperative Fasting
Gastric pH in Intubated Children - Part Two
Fasting (according to ASA, ESA or institutional guidelines) is an important strategy to minimize the risk of regurgitation, vomiting and pulmonary aspiration during general anaesthesia; the effect of fasting time for clear fluid…
- Trial name
- NCT02603094
- Testing
- clear fluid ingestion
- Where
- Switzerland
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University Children's Hospital, Zurich
Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
To evaluate the safety, efficacy and pharmacokinetics of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to <18 years).
- Trial name
- DIALOG (NCT01844765)
- Testing
- nilotinib
- Where
- 36 sites in United States, France and 11 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Dental Plaque, Saliva Altered
A Comparison Between Orthodontic and Non-orthodontic Patients on Oral Indexes and Salivary pH and Quality
This study aims to assess the caries susceptibility in pediatric patients aged 6-14 years old using Saliva-Check Buffer salivary tests. A total of 40 patients will be enrolled, divided into two groups: 1.
- Trial name
- NCT06922799
- Testing
- Saliva-Check Buffer test and periodontal charting
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Pavia
Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
This is a Phase 1-2, multicenter, international, single-arm, open-label study designed to identify a recommended dose of bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML…
- Conditions
- Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia
- Trial name
- NCT04258943
- Testing
- Bosutinib
- Where
- 59 sites in United States, France and 6 more
- Volunteers
- 60 people
- Sponsor
- Children's Oncology Group
Primary Hyperoxaluria, Primary Hyperoxaluria Type 1
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.
- Conditions
- Primary Hyperoxaluria, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3
- Trial name
- PHYOX8 (NCT05001269)
- Testing
- nedosiran
- Where
- 13 sites in United States, Canada and 9 more
- Volunteers
- 27 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Re-mineralization
Re-mineralization Effects of Sugar Free Chewing Gum Sweetened With Different Sugar-substitutes
The purpose of this study is to evaluate the clinical effect of chewing gum containing maltitol, on re-mineralization of early caries following daily chewing for 6 months by school children, compared to a xylitol gum, gum base…
- Trial name
- NCT02468388
- Testing
- maltitol, xylitol, gum base
- Where
- China
- Volunteers
- 482 people
- Sponsor
- Roquette Management (Shanghai) Co., Ltd.
Sickle Cell Disease
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
The investigators propose to determine the engraftment and transplant related morbidity and mortality after a non-myeloablative allogeneic hematopoietic stem cell transplant protocol using immune- suppressive agents and low-dose…
- Trial name
- NCT01499888
- Testing
- Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Illinois Chicago
Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
This study will assess the pharmacokinetics of imatinib in pediatric patients ages 1 to <4 years of age to help develop dosing regimens
- Conditions
- Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL), Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)
- Trial name
- NCT01066468
- Testing
- Gleevec/Glivec
- Where
- Russia
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals